Table 1 Patient information
N (%) | Clinical trial Cohort | Present study | |
|---|---|---|---|
Overall | 50 (100) | 44 (100) | |
Gender | Male | 36 (72) | 31 (70.5) |
Female | 14 (28) | 13 (29.5) | |
Age at diagnosis | = < 65 | 15 (30) | 14 (32) |
> 65 | 35 (70) | 30 (68) | |
MIPI | Low risk | 8 (16) | 7 (16) |
Medium risk | 15 (30) | 13 (29.5) | |
High risk | 23 (46) | 21 (47.7) | |
Missing | 4 (8) | 3 (6.8) | |
TP53 | Wild-type | 23 (46) | 20 (45.5) |
Deletions | 17 (34) | 14 (31.8)a | |
Mutated | 11 (25) | 11 (25)a | |
Missing | 1 (2.3) | 1 (2.3) | |
Ki-67 | < 30% | 17 (34) | 12 (27) |
> 30% | 21 (42) | 20 (46) | |
Missing | 12 (24) | 12 (27) | |
Overall Survival (months) | Median | 15.08 | 15.08 |
Number of deaths | 20 | 18 | |
Time to progression (months) | Median | 13.65 | 13.65 |
Number of deaths | 24 | 21 | |
Median Overall Survival (months) | 15.08 | 15.08 | |
Median Time to Progression (months) | 13.65 | 13.65 | |